About Allos Therapeutics, trial, which Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs to treat cancer. The company principal, pralatrexate, is a novel targeted antifolate designed to preferentially accumulate in cancer cells. In February 2009 the Company announced the final results from PROPEL, the company’s pivotal Phase 2 trial of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma .
The NDA is based on the results of the company pivotal Phase 2 trial based known as PROPEL . The PROPEL under an agreement under an agreement reached with the FDA under its Special Protocol Assessment, or SPA, process. Pralatrexate has orphan drug designation and fast track designation in the U.S. For the treatment of patients with T-cell lymphoma and orphan drug in Europe for the treatment of PTCL. The Company believes multicentrehat the PROPEL trial is the largest prospectively designed monotherapy study is carried out to date in patients with relapsed or refractory PTCL..You further recommend that particular patients with complex needs should not be allowed, work around NHS24 for specialized service , OOH. Such a rule, which palliative patients had with an local contact No. And the local service provided details in their condition is, for some time already in the Borders region of Scotland and to the North East of England were.. Authors also recommended the expansion patient -held noticed nurses, so that all visitors should be complementary routinely.